Efficacy and safety of avacopan in antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective cohort study in Japan

Abstract Background Avacopan, an oral C5a receptor antagonist, demonstrated efficacy as an alternative to glucocorticoid therapy in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in the phase 3 ADVOCATE trial. However, limited real-world data exist on the outcom...

Full description

Bibliographic Details

Published in:	BMC Rheumatology
Main Authors:	Genri Tagami, Makoto Yamaguchi, Hirokazu Sugiyama, Hiroshi Kinashi, Kentaro Imai, Keisuke Kamiya, Takayuki Katsuno, Takahiro Imaizumi, Shogo Banno, Yasuhiko Ito, Takuji Ishimoto
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Subjects:	Antineutrophil cytoplasmic autoantibody-associated vasculitis Avacopan Efficacy Remission Safety
Online Access:	https://doi.org/10.1186/s41927-025-00456-4